Associated tags: Knowledge, Patient, Central nervous system disease, Research, KOL, MDD, Psychotherapy, Polypharmacy, PTSD, Acute stress disorder, CNS, DSM-IV codes, Psychiatry, MDMA, Psilocybin, USFDA, TAS, Drug development, Major depressive disorder, TRD
Locations: UNITED KINGDOM, UNITED STATES OF AMERICA, CONNECTICUT, ITALY, EU, FRANCE, GERMANY, UNITED STATES
Knowledge,
Neurology,
Acadia Pharmaceuticals,
Pediatrics,
CDKL5,
Communication,
RTT,
Patient,
FOXG1,
Research,
Disorder,
Competitive landscape,
Rett syndrome,
Drug development,
USFDA HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title: Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033
Key Points:
- HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title: Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033
Rett Syndrome (RTT) is an orphan neurodevelopmental disorder for which no cure exists.
- The condition is clinically heterogenous; key patient types include typical or classical RTT and atypical RTT.
- Although the disorder is rare, it causes life-long impairment and severe symptoms requiring treatments such as antiepileptics and supportive therapies.
- Only one drug is USFDA approved for the treatment of RTT: Daybue (trofinetide), which is marketed by Acadia Pharmaceuticals.
Knowledge,
Neurology,
Acadia Pharmaceuticals,
Pediatrics,
CDKL5,
Communication,
RTT,
Patient,
FOXG1,
Research,
Disorder,
Competitive landscape,
Rett syndrome,
Drug development,
USFDA HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title: Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033
Key Points:
- HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title: Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033
Rett Syndrome (RTT) is an orphan neurodevelopmental disorder for which no cure exists.
- The condition is clinically heterogenous; key patient types include typical or classical RTT and atypical RTT.
- Although the disorder is rare, it causes life-long impairment and severe symptoms requiring treatments such as antiepileptics and supportive therapies.
- Only one drug is USFDA approved for the treatment of RTT: Daybue (trofinetide), which is marketed by Acadia Pharmaceuticals.
Retrieved on:
Wednesday, March 20, 2024
Knowledge,
Partnership,
Patient,
Research,
Tool,
Data collection,
Safety,
Market access,
TPP,
Data,
Pharmaceutical industry HARTFORD, Conn., March 20, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides; AI-Powered Tool Streamlining Payer Research for Optimal Results.
Key Points:
- HARTFORD, Conn., March 20, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides; AI-Powered Tool Streamlining Payer Research for Optimal Results.
- Thelansis understands the challenges pharmaceutical, medical technology, and biotech companies face when it comes to payer research.
- Case Study: Thelansis launched a Payer perception study in the United States, France, Italy, and Germany for a biotech company focusing on cell therapy development.
- "We are delighted with the results and experience of conducting the payer study through the PayerPro360 platform.
Retrieved on:
Wednesday, March 20, 2024
Knowledge,
Partnership,
Patient,
Research,
Tool,
Data collection,
Safety,
Market access,
TPP,
Data,
Pharmaceutical industry HARTFORD, Conn., March 20, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides; AI-Powered Tool Streamlining Payer Research for Optimal Results.
Key Points:
- HARTFORD, Conn., March 20, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides; AI-Powered Tool Streamlining Payer Research for Optimal Results.
- Thelansis understands the challenges pharmaceutical, medical technology, and biotech companies face when it comes to payer research.
- Case Study: Thelansis launched a Payer perception study in the United States, France, Italy, and Germany for a biotech company focusing on cell therapy development.
- "We are delighted with the results and experience of conducting the payer study through the PayerPro360 platform.
HARTFORD, Conn., March 5, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company, launched PayerPro360 To empower Pharma/Biotech with Robust Payer Insights.
Key Points:
- HARTFORD, Conn., March 5, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company, launched PayerPro360 To empower Pharma/Biotech with Robust Payer Insights.
- PayerPro360 by Thelansis - Empowering Pharma/Biotech with Robust Payer Insights.
- PayerPro360 is an innovative and user-friendly AI-based platform developed by Thelansis Knowledge Partners, designed to revolutionize Payer Research.
- Payer market research and insights generation are integral to pharma decision-making during drug development, premarket launch strategy, and post-marketing activities.
Retrieved on:
Thursday, February 22, 2024
Knowledge,
DSM-IV codes,
Esketamine,
TRD,
Major depressive disorder,
Drug development,
TAS,
USFDA,
Psilocybin,
MDMA,
Psychiatry,
CNS,
Patient,
Acute stress disorder,
PTSD,
Polypharmacy,
Psychotherapy,
MDD,
KOL,
Research,
Central nervous system disease,
Pharmaceutical industry Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."
Key Points:
- Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."
- According to an interviewed U.S.-based neurologist by Thelansis – "We desperately need disease-modifying treatments for many neurodegenerative conditions.
- As psychedelics would be beneficial for treatment-nonresponders or severe patients, the commercial opportunities are multiple for in-pipeline psychedelic therapies.
- What is the probable opportunity for Psychedelics (e.g., psilocybin, MDMA) to address the unmet needs of other TAs?
Retrieved on:
Thursday, February 22, 2024
Knowledge,
DSM-IV codes,
Esketamine,
TRD,
Major depressive disorder,
Drug development,
TAS,
USFDA,
Psilocybin,
MDMA,
Psychiatry,
CNS,
Patient,
Acute stress disorder,
PTSD,
Polypharmacy,
Psychotherapy,
MDD,
KOL,
Research,
Central nervous system disease,
Pharmaceutical industry Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."
Key Points:
- Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."
- According to an interviewed U.S.-based neurologist by Thelansis – "We desperately need disease-modifying treatments for many neurodegenerative conditions.
- As psychedelics would be beneficial for treatment-nonresponders or severe patients, the commercial opportunities are multiple for in-pipeline psychedelic therapies.
- What is the probable opportunity for Psychedelics (e.g., psilocybin, MDMA) to address the unmet needs of other TAs?
